Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name o	of entity:	AUSTCO HEALTHCARE LIMITED
ABN:	67 108 20	08 760

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Clayton Astles
Date of last notice	1 November 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest	-
(including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	(1) 29 December 2023
	(2) Between 20 December and 27 December 2023

⁺ See chapter 19 for defined terms.

No. of securities held prior to change	Direct	
No. of Securities field prior to change	Direct:	
	2,037,270 Ordinary Shares	
	1,396,276 Unlisted options with an exercise	
	price of \$0.13 expiring on 12 February 2024	
	price of \$0.13 expiring on 12 rebruiry 2024	
	1,350,000 Unlisted options with an exercise price of \$0.13 expiring on 11 September 2024	
	1,350,000 Unlisted options with an exercise price of \$0.215 expiring on 24 September 2025	
	677,486 Unlisted Performance Rights expiring 30 September 2026	
	Indirect: 1,440,643 Ordinary Shares (held via HSBC Custody Nominees (Australia) Limited for the Clayton Astles RRSP account)	
	91,804 Ordinary Shares (held via Clayton Astles ATF the Clayton Astles RRSP account)	
Class	(1) Unlisted options with an exercise price of \$0.13 expiring on 12 February 2024 and Ordinary Shares (2) Ordinary Shares	
Number acquired	270,000 Ordinary Shares	
Number disposed	(1) 270,000 Unlisted options with an exercise price of \$0.13 expiring on 12 February 2024; and (2) 206,204 Ordinary Shares	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	 (1) Unlisted Options exercised at \$0.13 into Ordinary Shares - \$35,100 (2) Ordinary Shares sold at \$0.195 cents per share - \$40,209.78 	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

No. of securities held after change	Direct:
	2,101,066 Ordinary Shares
	,
	1,126,276 Unlisted options with an exercise
	price of \$0.13 expiring on 12 February 2024
	TT TO A STATE OF
	1,350,000 Unlisted options with an exercise
	price of \$0.13 expiring on 11 September 2024
	1,350,000 Unlisted options with an exercise
	price of \$0.215 expiring on 24 September 2025
	677,486 Unlisted Performance Rights expiring
	30 September 2026
	T 10
	Indirect:
	1,440,643 Ordinary Shares (held via HSBC Custody Nominees (Australia) Limited for the
	Clayton Astles RRSP account)
	classon ribbles filles accounts
	91,804 Ordinary Shares (held via Clayton
	Astles ATF the Clayton Astles RRSP account)
Nature of change	(1) Exercise of 270,000 Unlisted options
Example: on-market trade, off-market trade, exercise of options,	into Ordinary Shares
issue of securities under dividend reinvestment plan, participation in buy-back	(2) On market trade of 206,204 Ordinary
	Shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A	
Interest after change	N/A	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?	
If prior written clearance was provided, on what date was this	N/A
provided?	

Appendix 3Y Page 4 01/01/2011

⁺ See chapter 19 for defined terms.